Consultation outcome

Consultation on Acnecide face gel and face wash

From:
Medicines and Healthcare products Regulatory Agency
Published
9 May 2019
Last updated
23 September 2019 鈥� See all updates
This consultation has concluded

Read the full outcome

PDF, 237 KB, 14 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Detail of outcome

皇冠体育app Medicines and Healthcare products Regulatory Agency (MHRA) has agreed to reclassify Acnecide Face Gel and Acnecide Face Wash from pharmacy (P) to general sale list (GSL) medicines for the treatment of mild acne affecting the face in adults and adolescents aged 12 years and over. See the public assessment report above for more information.

Feedback received

PDF, 41.1 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 264 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 255 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 122 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 84.9 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 93.2 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 94.5 KB, 2 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

PDF, 607 KB, 3 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Detail of feedback received

Consultation ARM 98 which summarises the proposal for pharmacy (P) to general sale list (P to GSL) reclassification of Acnecide Face Gel and Acnecide Face Wash was posted on the GOV.UK website on 9 May 2019. 皇冠体育app deadline for comments was given as 30 May 2019.

Eight responses were received. Four responses (from patients/members of the public) were in favour of the reclassification. Four responses (two from professional bodies/associations representing pharmacists, one from a pharmacy trade body and one from a pharmaceutical company regulatory affairs consultant) were not in favour.

Original consultation

Summary

We are seeking views on a proposal to make Acnecide Face 5% w/w Gel and Acnecide Face Wash 5% w/w Gel available from general sales outlets.

This consultation ran from
to

Consultation description

We are proposing to make Acnecide 鈥楩ace鈥� products available from general sales outlets with more limited conditions of use than the current pharmacy products.

皇冠体育app products are Acnecide Face 5% w/w Gel and Acnecide Face Wash 5% w/w Gel. 皇冠体育appy are preparations (face gel and face wash) containing benzoyl peroxide intended for use on the face.

皇冠体育appy are for the treatment of mild acne affecting the face in adults and adolescents aged 12 years and over.

皇冠体育app Commission on Human Medicines (CHM) has advised that Acnecide `Face鈥� products can be available as General Sale List (GSL) medicines.

This deadline for comments was 5:00pm on 30 May 2019.

Documents

PDF, 1.28 MB, 31 pages

Updates to this page

Published 9 May 2019
Last updated 23 September 2019 show all updates

  1. Uploaded public assessment report (PAR) and updated final outsome/summary text of consultation.

  2. First published.

Sign up for emails or print this page

Related content